<DOC>
	<DOCNO>NCT02369146</DOCNO>
	<brief_summary>The purpose phase II study evaluate safety , tolerability efficacy two multi-dose regimen UB-421 monotherapy replacement HAART HIV-1 infect adult virological suppression .</brief_summary>
	<brief_title>To Investigate Safety Efficacy UB-421 Monotherapy HIV Infected Adults</brief_title>
	<detailed_description>This open-label , Phase II study evaluate safety , tolerability efficacy two multi-dose regimen UB-421 monotherapy replacement HAART HIV-1 infect adult virological suppression . In study , approximately 28 subject enrol receive one two UB-421 regimen monotherapy replacement HARRT treatment . Subjects assign Cohort 1 receive UB-421 infusion 10 mg/kg weekly 8 week ; subject assign Cohort 2 receive UB-421 infusion 25 mg/kg bi-weekly 16 week .</detailed_description>
	<criteria>HIV1 seropositive Aged 20 year old Have receive HAART treatment CD4+ T cell count â‰§ 350 cells/mm3 HIV1 plasma RNA level remain limit Were breastfeed woman Subjects negative serum pregnancy test result screen visit woman childbearing potential Subjects agree use birth control barrier ( female male condom ) entire study period Subjects sign inform consent undergo study procedure Any active infection except HIV , require immediate therapy Any active AIDSdefining illness per Category B Category C condition accord U.S. Centers Disease Control Prevention ( CDC ) Classification System HIV Infection Any document CD4+ T cell count &lt; 200 cells/mm3 within past 12 week screen visit Any significant disease ( HIV1 infection ) clinically significant finding , include psychiatric behavioral problem , determine screening , medical history , and/or physical examination , investigator 's opinion , would preclude subject participate study Any vaccination within 8 week prior first dose study drug Any immunomodulating therapy ( include interferon steroid ) systemic chemotherapy within 12 week prior first dose study drug Any illicit intravenous drug within 12 week prior first dose study drug Any current alcohol illicit drug use , investigator 's opinion , interfere subject 's ability comply dose , visit schedule protocol evaluation More one change HAART regimen virologic failure</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>